SEC Form 4 · accession 0001140361-15-045390
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Michael J. Abrams
Officer — Exec. VP & Chief Discovery Off
Period of report
Jul 9, 2015
Accepted (ET)
Dec 22, 2015 · 5:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $17.57 | Jul 9, 2015 | A | 35,000 | A | — | Mar 30, 2025 | Common shares | 35,000 | 35,000 | D |
Explanation of responses
- F1The option vests as follows: 1/3 on 3/30/2016; 1/3/ on 3/30/2017; and 1/3 on 3/30/2018.